American Diabetes Association

Empagliflozin, a diabetes drug that controls glucose levels, may also help ameliorate erectile dysfunction in patients with type 2 diabetes mellitus.

Approved by the US Food and Drug Administration (FDA) just over 4 years ago, linagliptin (Tradjenta) can help protect against renal injury in patients with type 2 diabetes.

Oxidative stress plays an important role in the ability for dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, to effectively ease diabetic nephropathy, according to lead author Takashi Hatanaka of Nagoya University. The study will be presented in a poster session on June 6 at the American Diabetes Association 75th Scientific Sessions in Boston, MA.

Phase III trial shows that transplanted purified human pancreatic islets safely restored sustained near-normoglycemia and provided protection from severe hypoglycemia in patients with long-standing type 1 diabetes and iatrogenic hypoglycemia.

Researchers find that the ratio of total cholesterol to HDL is a significant predictor for CVD in type 1 diabetes patients who are not using lipid-lowering drugs, and that the ratio of total cholesterol to HDL is a more reliable marker for risk when considering primary prevention.

Researchers have identified a previously unrecognized mechanism for SGLT2 inhibitors in the regulation of glucagon and gluconeogenic gene expression.

Patients with type 1 diabetes who had more depressive symptoms measured at baseline and over time appear to be at an increased risk of mortality, even after allowing for likely mediators.

Patients with type 2 diabetes and inadequate glycemic control treated with dapagliflozin plus metformin and sulfonylurea experienced sustained improvements in HbA1c, fasting plasma glucose, weight loss, and systolic blood pressure over 52 weeks.

Patients between the ages of 55 and 80 with type 2 diabetes treated with canagliflozin for more than 100 weeks experienced significant reductions in HbA1C, fasting plasma glucose, bodyweight, and systolic blood pressure.

Study results show long-term treatment with empagliflozin was well tolerated and associated with reductions in HbA1c, bodyweight, and systolic blood pressure compared with placebo and sitagliptin.

Study results presented at ADA 2014 show combination treatment with metformin plus linagliptin delivered consistent HbA1c reductions across different subgroups of patients newly diagnosed with type 2 diabetes, with decreased risk of hypoglycemia.

Study results show that an alternative to currently-marketed injectable agents retains the efficacy of GLP-1 mimetics, while reducing gastrointestinal adverse events and providing the convenience of oral dosing.

Results from the largest population-based, case-control study on the link between incretin therapy and pancreatitis conducted to date indicate that treatment with this class of medications does not confer increased risk of developing pancreatitis.

Combination treatment with insulin degludec and liraglutide was associated with long-term reductions in HbA1c, reduced hypoglycemia risk, and fewer gastrointestinal side effects compared to treatment with the individual medications alone in patients with diabetes.

Patients treated with a new, more concentrated insulin glargine formulation experienced similar glycemic control with fewer nocturnal and daytime hypoglycemic events compared with patients treated with the current formulation of the product.

Study results presented at ADA 2014 show Eli Lilly's investigational long-acting basal insulin analog to have similar clinical efficacy in reducing HbA1c levels as a currently approved injectable insulin glargine product, with a comparable side effect profile.

By adopting a comprehensive set of case management policies for the care of diabetic and hyperglycemic patients, Johns Hopkins Hospital improved in-hospital mortality rate, reduced length of stay, and reduced hyperglycemia.

Exposure to insulin glargine and metformin did not cause increased risk of cancer or worse cancer outcomes.

Results of a three-year trial of the experimental GLP-1 receptor agonist albiglutide showed that it had a better effect on HbA1c, fasting blood glucose, and body weight than two comparator drugs.

Prescription-strength doses of vitamin D improve highly prevalent comorbidities among diabetic women, such as depression and pain, and also improve risk factors such as excess weight and high blood pressure.

While the current ADA guidelines recommend targeting HbA1c levels to below 8% for high-risk patients with diabetes, reducing the level to 5.7% dose not raise CVD or overall mortality risk, according to a recent study.

A novel algorithm for patient self-adjustment of prandial insulin dose could make it easier for patients who are poorly-controlled on basal insulin to add meal-time insulin.

In patients with type 2 diabetes currently taking metformin, treatment with combination exenatide plus insulin glargine decreased fasting glucose and resulted in greater weight loss compared to treatment with insulin lispro plus insulin glargine.

Study shows dulaglutide improved glycemic control in patients at 52 weeks compared to sitagliptin, but with a higher rate of adverse events.

Study shows a combination of liraglutide and the genetically modified insulin analog degludec was safe and improved HbA1c levels, weight loss, and hypoglycemia outcomes in patients with type 2 diabetes.

News and updates about the American Diabetes Association 73rd Scientific Sessions.

David Sacks, MD talks about the American diabetes association meeting.

More patients in the RIDE and RISE trials treated with the VEGF inhibitor showed improvements in vision test scores compared to patients who received placebo.

Treatment with metformin and diet and lifestyle modifications both are cost-effective means of decreasing diabetes risk and improving quality of life.

Researchers are investigating novel ways to preserve beta cell function in type 1 diabetes patients and enhance the body's ability to produce its own insulin.